About the Study

VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Clinical Site Contact Information

King's College Hospital
Denmark Hill, Brixton,,
UK

Principal Investigator
Principal Investigator
Jonathan William

jonathan.w@gmail.com.test
+44 20 3299 9000

Book an appointment